Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about BACE1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Beta-site APP Cleaving Enzyme 1 (BACE1) is the rate-limiting enzyme in amyloid-beta production, performing the first cleavage of APP in the amyloidogenic pathway. BACE1 activity increases with age and in AD brains, driven by oxidative stress, inflammation, and impaired trafficking. BACE1 inhibitors were pursued as AD therapeutics but clinical trials (verubecestat, atabecestat, elenbecestat) failed due to cognitive worsening and synaptic toxicity, likely from inhibiting BACE1 cleavage of neuregulin-1 and other substrates critical for myelination and synaptic function. BACE1 knockout mice show seizures, hypomyelination, and behavioral deficits. Current approaches focus on partial BACE1 inhibition or substrate-selective strategies to reduce Abeta without off-target effects.
No AI portrait yet
| Gene Symbol | BACE1 |
| Full Name | Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 |
| Chromosome | 11q13.2 |
| Protein Type | Protease |
| Target Class | Protease |
| Function | BACE1 is a transmembrane aspartyl protease that catalyzes the ectodomain shedding of numerous type I membrane proteins |
| Mechanism of Action | Small molecule inhibitor of aspartyl protease activity |
| Druggability | Medium (0.48) |
| Clinical Stage | Phase III |
| Pathways | Amyloid, Apoptosis, Lipid Metabolism, Nf-Κb, Synaptic Plasticity |
| UniProt ID | Q15118 |
| NCBI Gene ID | 23626 |
| Ensembl ID | ENSG00000186318 |
| OMIM | 604252 |
| GeneCards | BACE1 |
| Human Protein Atlas | BACE1 |
| Associated Diseases | AD, aging, Als, Alzheimer, Alzheimer's disease |
| Known Drugs/Compounds | aducanumab, BACE1 siRNA, DHA, Ginsenosides Rh4, lecanemab, Liquiritigenin |
| Interactions | ABCA1, ABCA7, ACE, ACETYL-COA, ACHE, Actin |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Palmitoylation-Targeted BACE1 Trafficking Disrupto |
| KG Connections | 1663 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
flowchart TD
BACE1["BACE1
beta-secretase"]
APP["APP
Amyloid Precursor
Protein"]
Abeta["Abeta peptides
Amyloid Beta"]
AD["Alzheimer's
Disease"]
ALS["ALS"]
MS["Multiple
Sclerosis"]
TNF["TNF-alpha
Pro-inflammatory
Cytokine"]
IL6["IL-6
Pro-inflammatory
Cytokine"]
NFKB["NF-kappaB
Transcription
Factor"]
JAK2_STAT1["JAK2-STAT1
Signaling
Pathway"]
C1Q["C1Q
Complement
Protein"]
AMPK["AMPK
Energy Sensor"]
Liquiritigenin["Liquiritigenin
Natural Inhibitor"]
Ginsenosides["Ginsenosides Rh4
Natural Inhibitor"]
BACE1_siRNA["BACE1 siRNA
Therapeutic
Inhibitor"]
Neuroinflammation["Neuroinflammation"]
Aging["Aging
Process"]
TNF -->|"activates"| BACE1
IL6 -->|"activates"| BACE1
NFKB -->|"activates"| BACE1
JAK2_STAT1 -->|"regulates"| BACE1
C1Q -->|"regulates"| BACE1
BACE1 -->|"cleaves"| APP
APP -->|"produces"| Abeta
BACE1 -->|"promotes"| Abeta
Abeta -->|"drives"| AD
BACE1 -->|"associated_with"| AD
BACE1 -->|"therapeutic_target"| ALS
BACE1 -->|"therapeutic_target"| MS
AMPK -->|"inhibits"| BACE1
Liquiritigenin -->|"inhibits"| BACE1
Ginsenosides -->|"inhibits"| BACE1
BACE1_siRNA -->|"inhibits"| BACE1
BACE1 -->|"biomarker_for"| Neuroinflammation
BACE1 -->|"biomarker_for"| Aging
style BACE1 fill:#006494
style AMPK fill:#1b5e20
style Liquiritigenin fill:#1b5e20
style Ginsenosides fill:#1b5e20
style BACE1_siRNA fill:#1b5e20
style TNF fill:#ef5350
style IL6 fill:#ef5350
style Abeta fill:#ef5350
style AD fill:#5d4400
style ALS fill:#5d4400
style MS fill:#5d4400
style Neuroinflammation fill:#5d4400
style NFKB fill:#4a1a6b
style JAK2_STAT1 fill:#4a1a6b
style C1Q fill:#4a1a6b| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:BACE1 | data_in | dataset_row | 0.00 |
| benchmark_ot_ad_answer_key:BACE1 | data_in | dataset_row | 0.00 |
| ds-b3d65f2c2ca6 | provides_data_for | dataset | 1.00 |
| ds-83b31ef18d49 | provides_data_for | dataset | 1.00 |
| ds-6784494f1741 | provides_data_for | dataset | 1.00 |
| Alzheimer | therapeutic_target | disease | 0.95 |
| Alzheimer'S Disease | upregulates | disease | 0.95 |
| AMYLOID-Β | associated_with | entity | 0.95 |
| Abeta | upregulates | protein | 0.92 |
| GABAAR beta subunits | associated_with | protein | 0.90 |
| Aβ production | enhances | pathway | 0.90 |
| Aβ | causes | compound | 0.90 |
| CLUSTERIN | regulates_expression | protein | 0.90 |
| Amyloid beta | causes | protein | 0.90 |
| GABAAR currents | inhibits | protein | 0.90 |
| Cochlear function | required_for | process | 0.90 |
| ALZHEIMER'S DISEASE | contributes_to | disease | 0.90 |
| AMYLOID-BETA | produces | protein | 0.90 |
| Amyloid-beta 1-42 | associated_with | protein | 0.90 |
| APP | cleaves | protein | 0.90 |
| Amyloid Deposition | involved_in | process | 0.89 |
| Neurodegeneration | activates | disease | 0.85 |
| Neuritic Plaque Formation | contributes_to | process | 0.85 |
| Aging | activates | disease | 0.85 |
| Trans-Golgi Network | expressed_in | cell_type | 0.85 |
| Hyperthyroidism | associated_with | disease | 0.85 |
| Alzheimer | activates | disease | 0.85 |
| Alzheimer Disease | upregulates | disease | 0.80 |
| Amyloid-beta | participates_in | protein | 0.80 |
| PKA | regulates | protein | 0.80 |
| hippocampus | expressed_in | brain_region | 0.80 |
| HDAC6 | interacts_with | protein | 0.80 |
| Recycling Endosomes | expressed_in | cell_type | 0.80 |
| Alzheimer's Disease | implicated_in | disease | 0.80 |
| GABAAR β subunits | associated_with | protein | 0.80 |
| Neural hyperexcitability | causes | disease | 0.80 |
| GDF15 | regulates | protein | 0.80 |
| EndMT | associated_with | pathway | 0.80 |
| Alzheimer's disease | secreted_by | disease | 0.80 |
| CAMP | regulates | compound | 0.80 |
| Brain endothelial dysfunction | causes | disease | 0.80 |
| Wnt signaling | participates_in | pathway | 0.80 |
| Neurodegeneration | involved_in | disease | 0.80 |
| Blood-Brain Barrier | therapeutic_target | pathway | 0.80 |
| GENES | therapeutic_target | gene | 0.80 |
| ALZHEIMER'S DISEASE | activates | gene | 0.80 |
| ALZHEIMER'S DISEASE | therapeutic_target | gene | 0.80 |
| ALZHEIMER | therapeutic_target | gene | 0.80 |
| Als | activates | disease | 0.75 |
| Alzheimer | expressed_in | disease | 0.75 |
| Source | Relation | Type | Str |
|---|---|---|---|
| entities-app-protein | interacts_with | wiki | 0.00 |
| benchmark_ot_ad_answer_key:BACE1 | data_in | dataset_row | 0.00 |
| benchmark_ot_ad_answer_key:BACE1 | data_in | dataset_row | 0.00 |
| genes-bace1 | linked_to | wiki_page | 1.00 |
| ALZHEIMER'S DISEASE | associated_with | disease | 1.00 |
| ds-b3d65f2c2ca6 | data_in | dataset | 1.00 |
| ds-6784494f1741 | data_in | dataset | 1.00 |
| ds-83b31ef18d49 | data_in | dataset | 1.00 |
| AMYLOID | associated_with | gene | 1.00 |
| PPARGC1A | regulates | gene | 0.95 |
| PGC1Α | regulates | entity | 0.95 |
| SGMS1 Inhibition | downregulates | mechanism | 0.92 |
| SGMS1 | modulates | protein | 0.90 |
| SMS1 | modulates | protein | 0.90 |
| h-441b25ba | targets_gene | hypothesis | 0.90 |
| hyp-SDA-2026-04-12-20260411-082446-2c1c9e2d-2 | targets_gene | hypothesis | 0.90 |
| P60TRP | inhibits | protein | 0.89 |
| PCBP2 | regulates | protein | 0.88 |
| FLOATLIN1 | interacts_with | protein | 0.88 |
| LEAD | upregulates | drug | 0.87 |
| SREBP2 | regulates | protein | 0.87 |
| DHA | downregulates | drug | 0.85 |
| CAV1 | modulates | protein | 0.85 |
| Hyperthyroidism | upregulates | disease | 0.85 |
| TAU | associated_with | protein | 0.82 |
| APP | inhibits | gene | 0.82 |
| Presenilin 1 | regulates | protein | 0.80 |
| MIRNAS | targets | gene | 0.80 |
| DHA | inhibits | compound | 0.80 |
| h-441b25ba | targets | hypothesis | 0.80 |
| APP | secreted_by | gene | 0.80 |
| TFRC | co_expressed_with | protein | 0.80 |
| AMYLOID | inhibits | gene | 0.74 |
| APP | cleaves | gene | 0.74 |
| APP | interacts_with | gene | 0.74 |
| APP | mediates | gene | 0.70 |
| ASTROCYTE | associated_with | cell_type | 0.70 |
| ACHE | interacts_with | gene | 0.70 |
| APOE | expresses | gene | 0.70 |
| ACHE | inhibits | gene | 0.70 |
| ACHE | targets | gene | 0.70 |
| ADAM10 | protects_against | gene | 0.70 |
| ADAM17 | activates | gene | 0.70 |
| ASTROCYTE | expresses | cell_type | 0.70 |
| ASTROCYTE | inhibits | cell_type | 0.70 |
| AIF1 | degrades | gene | 0.70 |
| APP | expresses | gene | 0.70 |
| NEURON | causes | cell_type | 0.70 |
| CHOLESTEROL | regulates | phenotype | 0.70 |
| entities-remternetug | interacts_with | wiki | 0.70 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imb | 0.743 | neurodegeneration | What are the physiological functions of |
| SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso | 0.734 | neurodegeneration | What molecular mechanisms link elevated |
| SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct | 0.732 | neurodegeneration | How do sphingomyelin/ceramide ratios spe |
| Palmitoylation-Targeted BACE1 Trafficking Disruptors | 0.693 | neurodegeneration | Lipid raft composition changes in synapt |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.743
neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.734
neurodegeneration | 2026-04-12 | 3 hypotheses Top: 0.887
neurodegeneration | 2026-04-03 | 14 hypotheses Top: 0.803
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.756
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. [PMID:33803217] | Chang CH, Lin CH, Lane HY | Int J Mol Sci | 2021 | 1 |
| Blocking palmitoyl-transferase activity reduces BACE1 membrane localization and [PMID:23395894] | Unknown | Molecular Neurodegeneration | 0 | |
| Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] | ["Hsu-Heng Lin", "Hui-An Chen", "Shyh-Je | Molecular genetics & genom | 2026 | 0 |
| Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] | ["Aron Park", "Baeki E Kang", "Eun-Ju Ji | Genes & genomics | 2026 | 0 |
| A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] | Yu X MD, Lei J MSc, Du X MSc, He Y MSc, | Int J Surg | 2026 | 0 |
| Plasma metabolites may inhibit childhood obesity by regulating ferroptosis throu [PMID:41249848] | Wang JG, Pan XH, Li Y | Int J Obes (Lond) | 2026 | 0 |
| Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] | Park A, Kang BE, Jin EJ, Kim HJ, Lee CW | Genes Genomics | 2026 | 0 |
| AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160] | Jia J, Gan Y, Li J, Li L, Meng H et al. | Adv Sci (Weinh) | 2026 | 0 |
| Amyloid-β fibrils accumulated in preeclamptic placentas suppress cytotrophoblast [PMID:41558820] | Nishioka K, Ikezaki M, Iwahashi N, Araka | Life Sci Alliance | 2026 | 0 |
| Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] | Lin HH, Chen HA, Lin SJ, Hsu RH, Lee NC | Mol Genet Genomic Med | 2026 | 0 |
| An anti-inflammatory neuroenhancer mitigates amyloid-β pathology to improve Alzh [PMID:41696149] | Fang W, Zhao J, Li L, Wang Y, Xu ZP et a | Mater Today Bio | 2026 | 0 |
| Neuregulin1-ErbB4 Signaling Involved in Acupuncture Promoting Myelin Regeneratio [PMID:41801841] | Shen J, Zhao Y, Jiang C, Huang Y, Wang L | J Vis Exp | 2026 | 0 |
| Intranasal administration of neural stem cell-derived extracellular vesicles pre [PMID:41923110] | Natale Francesca; Dellaria Alice; Nifo S | Alzheimer's research & the | 2026 | 0 |
| Salvianolic acid a inhibits neuroinflammation and ameliorates Alzheimer's diseas [PMID:41930874] | Xiao S, Han Y, Yan J, Wu L, Lin H et al. | Int Immunopharmacol | 2026 | 0 |
| Alzheimer's disease basics: we all should know. [PMID:40639927] | Das S | Neurological research | 2026 | 0 |
| Demethyleneberberine attenuates combined cognitive and metabolic dysfunctions in [PMID:41482106] | Kaur A, Singh S, Singh M, Silakari P, Ma | Experimental neurology | 2026 | 0 |
| AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition [PMID:41524160] | Jia J, Gan Y, Li J, Li L, Meng H, Sun M, | Advanced science (Weinheim, Ba | 2026 | 0 |
| A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] | Yu X, Lei J, Du X, He Y, Peng W, Yang R, | International journal of surge | 2026 | 0 |
| AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategie [PMID:41268687] | Chen J, Liu B, Yao X, Yang X, Sun J et a | CNS Neurosci Ther | 2025 | 0 |
| AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategie [PMID:41268687] | Chen J, Liu B, Yao X, Yang X, Sun J, Yi | CNS neuroscience & therapeutic | 2025 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.75 · 2026-04-16
closed · Rounds: 4 · Score: 0.76 · 2026-04-16
closed · Rounds: 4 · Score: 0.79 · 2026-04-12
closed · Rounds: 5 · Score: 0.93 · 2026-04-11
closed · Rounds: 4 · Score: 0.89 · 2026-04-06
closed · Rounds: 4 · Score: 0.95 · 2026-04-06
closed · Rounds: 4 · Score: 0.95 · 2026-04-03